Heineken Hosts Biggest UEFA Champions League Trophy Tour in Africa
11.5.2022 09:59:00 EEST | Business Wire | Press release
In its continuing effort to bring the UEFA Champions League (UCL) experience closer to more football fans around the world, Heineken has staged its most elaborate Trophy Tour in Africa yet. The 10-day tour, which ended on April 13 in Abuja, Nigeria, ahead of the 2022 final match on May 28, included several public events that featured the UCL trophy at major stops in the Democratic Republic of Congo, Mozambique, Ethiopia, and Nigeria. Fans from Rwanda and Congo Brazzaville also attended the tour in Nigeria and DRC respectively.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509006222/en/
Clarence Seedorf on tour with the UEFA Champions League trophy in Ethiopia, as part of the pan-African tour, courtesy of Heineken.
The events around the tour included open-truck city parades, novelty matches with local celebrities, UCL quarter final match viewings, fan meet and greets, photo sessions, media rounds, Afrobeats concerts, and visits to government ministries in charge of football.
Heineken, sold in 192 countries around the world, has been a sponsor of the UEFA Champions League since 2005 and the company’s leadership said its Africa-wide trophy tour for the 2021/2022 season was structured to reach 50,000 Africans directly while an estimated 10 million more are reached via media coverage.
A highlight of the trophy tour was a Heineken-sponsored football match in Lagos, Nigeria. It pitted Nigerian music superstars and football legends against senior staff of Nigerian Breweries, which is the local Heineken brewer, and the Trophy Tour Ambassador, professional coach and former Dutch international midfielder, Clarence Seedorf.
BET Awards-winning Afrobeats star Davido captained Team Nigeria, which had ex-Nigerian internationals Austin Jay Jay Okocha, Daniel Amokachi, and Taribo West. Also on the squad were rapper M.I. Abaga, R&B singer Darey, and Nigerian Breweries Marketing Director, Emmanuel Oriakhi. Seedorf led Team Heineken, playing, among others, Nigerian Breweries Finance Director, Rob Kleinjan; and the company’s Supply Chain Director, Martin Kochl.
The novelty match preceded an Afrobeats concert that was headlined by African superstar, Davido and Peruzzi, another topflight Nigerian singer. Members of the Heineken management team and Seedorf then met with the Nigerian Minister of Youth and Sports Development, Sunday Dare, at the MKO Abiola stadium in Abuja, the country’s capital.
The Union of European Football Associations, the umbrella organisation for 55 national football associations across Europe, organizes the Champions League as an annual competition among top-division football clubs. The 2022 final match is slated for May 28 at the Stade de France in Paris.
“The goal of the Trophy Tour is to inspire a new generation of African footballers and appreciate fans for their love of the UEFA Champions League and Heineken,” said Heineken’s Senior Global Director, Bram Westerbrink.
The continent’s importance to the growth of football and the UCL is evident, Bram also noted. Several European clubs in the English, French, Italian, Spanish, and German leagues have notable African following, with many of the fans organising meetups and celebrations when their favourite teams record tournament successes. With more than 100 Africans currently playing professionally, over 25 Champions League winners from Africa, and about 300 million African fans, football has taken hold as the most popular sport on the continent.
“This is why Heineken is proud to celebrate its association with the UEFA Champions League,” said Hans Erik Tuijt, Director, Global Heineken Sponsorships, adding that Heineken has the highest awareness on the continent as a sponsor of the UEFA Champions League.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509006222/en/
Contact information
Enitan Kehinde
Enitan@bhmng.uk
+447899410249
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom